Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TEVA WITH A TWIST: LEMMON GENERICS' PARENT UP 1-5/8 IN OTHERWISE SOUR MARKET

Executive Summary

Teva Pharmaceutical Industries is gaining broader recognition with investors as a generics company with a twist: in addition to five ANDA approvals in 1993 for the company's Lemmon generics U.S. subsidiary, Teva is poised to announce results from a Phase III trial for its multiple sclerosis treatment, COP-1. Teva's new appeal moved the stock ahead 1-5/8 to 33-3/8 in February.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024140

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel